EUVIMEDEUVIMED entdecken
Fallbericht

Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series

Nigel Wei-Peng Seng, Jason Bae Barco, Marc Hai-Liang Wong, Kai-Xiong Lim, Wee-Ming Peh, Choong-Tatt Ng, Tim Cushway, Fung-Joon Foo, Frederick Hong-Xiang Koh

Transfusion Medicine · 2023

DOI: 10.1111/tme.12980 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Transfusion Medicine, 2023. Verfasst von Nigel Wei-Peng Seng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Health Holdings, Singapore, Singapore. Hauptthemen laut MEDLINE: Hypophosphatemia, Anemia, Iron-Deficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This case series would like to highlight hypophosphatemia related to ferric carboxymaltose and its adverse clinical consequences.

Background

Intravenous iron supplementation is a good alternative to oral iron replacement in iron deficiency anaemia due to its ability to correct iron deficit with minimal infusions without incurring the gastrointestinal side effects of oral iron replacement. Ferric carboxymaltose is one common formula for intravenous iron supplementation. However, an increasingly recognised adverse side‐effect of intravenous ferric carboxymaltose is hypophosphatemia. There has been increasing reports and studies highlighting hypophosphatemia related to intra‐venous iron therapy. Though initially thought to be transient and asymptomatic, recent studies have shown that persistent hypophosphatemia in iron therapy can result in debilitating disease including myopathy, fractures and osteomalacia.

Methods

A retrospective analysis of all patients who had ferric carboxymaltose was performed.

Results

We highlight 3 cases where hyposphatemia affected the clinical outcomes.

Conclusion

With the increased use of IV iron it is important to be aware of the high potential for hypophosphatemia secondary to ferric carboxymaltose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypophosphatemiaAnemia, Iron-DeficiencyHumansRetrospective StudiesFerric CompoundsIronAdministration, IntravenousMaltose

Stichwörter der Autor:innen

Fibroblast Growth Factor-23anaemiaanaemia, iron-deficiency/drug therapyferric carboxymaltoseferric compounds/adverse effectshumanshypophosphatemia/chemically inducedinfusionintravenousiron

Substanzen

Ferric CompoundsIronferric carboxymaltoseMaltose

Autor:innen und Institutionen

  • Ministry of Health Holdings, Singapore, Singapore.
  • Sengkang General Hospital, Singapore, Singapore.
  • The Iron Suites Medical Centre, Singapore, Singapore.

Zitieren

APA

Seng, N. W., Barco, J. B., Wong, M. H., Lim, K. X., Peh, W. M., Ng, C. T., Cushway, T., Foo, F. J., & Koh, F. H. (2023). Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series. Transfusion Medicine. https://doi.org/10.1111/tme.12980

Vancouver

Seng NW, Barco JB, Wong MH, Lim KX, Peh WM, Ng CT, et al. Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series. Transfusion Medicine. 2023. doi:10.1111/tme.12980

BibTeX
@article{Seng2023,
  author = {Seng, Nigel Wei-Peng and Barco, Jason Bae and Wong, Marc Hai-Liang and Lim, Kai-Xiong and Peh, Wee-Ming and Ng, Choong-Tatt and Cushway, Tim and Foo, Fung-Joon and Koh, Frederick Hong-Xiang},
  title = {Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series},
  journal = {Transfusion Medicine},
  year = {2023},
  doi = {10.1111/tme.12980}
}
Kostenlos starten →